When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 21 Apr 2025
Last updated: 22 Jul 2022

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • amenorrhoea or oligomenorrhoea
  • infertility
  • galactorrhoea
  • loss of sexual desire (libido)
  • erectile dysfunction
  • visual deterioration (e.g., temporal hemianopia)

Other diagnostic factors

  • osteoporosis
  • ophthalmoplegia
  • headaches

Risk factors

  • genetic predisposition (e.g., presence of mutation resulting in multiple endocrine neoplasia-1 [MEN-1], familial isolated pituitary adenoma [FIPA])
  • oestrogen therapy
  • male sex, 30 to 60 years of age
  • female sex, 20 to 50 years of age

Diagnostic investigations

1st investigations to order

  • serum prolactin
  • pituitary MRI
  • computerised visual-field examination

Treatment algorithm

Contributors

Authors

Niamh Martin, MB ChB, PhD, FRCP

Reader in Endocrinology

Imperial Centre for Endocrinology

Department of Metabolism, Digestion and Reproduction

Imperial College London

London

UK

Disclosures

NM declares that she has no competing interests.

Acknowledgements

Dr Niamh Martin would like to gratefully acknowledge Dr Ilan Shimon, the previous contributor to this topic.

Disclosures

IS receives consultancy and lecturing fees from Pfizer, Israel, and is an author of a number of references cited in this topic.

Peer reviewers

Mark Molitch, MD

Professor

Division of Endocrinology

Northwestern University Feinberg School of Medicine

Chicago

IL

Disclosures

MM is an author of a number of references cited in this topic.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Wildemberg LE, Fialho C, Gadelha MR. Prolactinomas. Presse Med. 2021 Dec;50(4):104080.Full text  Abstract

Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.Full text  Abstract

Xia MY, Lou XH, Lin SJ, et al. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018 Jan;59(1):50-61. Abstract

Reference articles

A full list of sources referenced in this topic is available here.

Use of this content is subject to our disclaimer